Immunisation of young children against influenza — evidence review

Influenza is a highly contagious viral infection and poses a serious burden, especially for children under 5 years of age due to an increased risk of severe illness and hospitalization. Influenza-related infant mortality during the pre-Covid period was reported annually. The highest mortality rate was regularly recorded among young children and especially children under the age of 6 months. Influenza vaccination in young children has been proven to be safe and effective. Influenza vaccination of young children not only protects this vulnerable age group, but is also an important way to reduce the transmission of influenza to others at risk, as well as reduce the use of healthcare services, including the use of antibiotics. Immunization against influenza in the current epidemiological conditions is especially relevant, since during the ongoing COVID-19 pandemic, it is impossible to predict the intensity and timing of the upcoming influenza seasonal rise. To prevent influenza in children, any licensed influenza vaccine that meets the indications is used, however, in modern conditions, the priority in influenza prevention is the use of quadrivalent vaccines that ensure the development of the most stable immune response against key strains of influenza viruses. Quadrivalent influenza vaccines include two influenza B strains of the Yamagata and Victoria B lines in addition to influenza A strains (H1N1 and H3N2). Studies have shown that immunization with the quadrivalent vaccine, including in young children, is well tolerated and effectively protects against any circulating and antigenically matched strains of influenza viruses. Russian-made quadrivalent inactivated full-cycle influenza vaccine for the prevention of seasonal influenza is the first quadrivaccine in the Russian Federation approved for use in influenza immunization of children from 6 months of age and pregnant women. The vaccine complies with all World Health Organization recommendations on the composition and amount of hemagglutinin of an influenza virus strain – it contains 15 μg of influenza virus hemagglutinin of each strain (А(N1N1), A(N3N2), B line Yamagata, B line Victoria); does not contain immunomodulators, adjuvants and preservatives; meets the immunogenicity criteria for inactivated influenza vaccines adopted in the European Union and the Russian Federation.

1. Приказ Министерства здравоохранения Российской Федерации от 06.12.2021 № 1122н «Об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок» (Зарегистрирован 20.12.2021 № 66435) [Order of the Ministry of Health of the Russian Federation dated December 6, 2021 No. 1122n «On approval of the national calendar of preventive vaccinations, the calendar of preventive vaccinations for epidemic indications and the procedure for conducting preventive vaccinations» (Registered on December 20, 2021 No. 66435) (in Russ.)]

2. Пшеничная Н. Ю., Карева Е. Н., Ленева И. А., и др. Фармакоэпидемиологическое исследование COVID-19 в Российской Федерации ЭГИДА-2020 // Терапевтический архив. 2021; 93 (11): 1306-1315. DOI: 10.26442/00403660.2021.11.201206 [Pshenichnaya N. Y., Kareva E. N., Leneva I. A., et al. Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 // Terapevticheskii arkhiv. 2021; 93 (11): 1306-1315. (in Russ.) DOI: 10.26442/00403660.2021.11.201206]

3. Сведения об инфекционных и паразитарных заболеваниях за январь— декабрь 2018 в РФ // Детские инфекции. 2019; 18 (1): 5. [Data on infectious and parasitic diseases for January-December 2018 in the Russian Federation. Children's infections. 2019; 18(1):5. (in Russ.)]

4. Caini S., Kusznierz G., Garate V. V., et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century // PLoS One. 2019 Sep 12; 14 (9): e0222381. DOI: 10.1371/journal.pone.0222381

5. Gill P. J., Ashdown H. F., Wang K., et al. Identification of children at risk of severe influenza-related complications in primary and ambulatory care: a systematic review and meta-analysis // Lancet Respir Med. 2014; (published online Dec 4.) http://dx.doi.org/10.1016/S2213-2600(14)70252-8

6. Булгакова В. А., Поромов А. А., Грекова А. И., и др. Фармакоэпидемиологическое исследование течения гриппа и других ОРВИ в группах риска // Терапевтический архив. 2017;89 (1): 62-71. DOI: 10.17116/terarkh201789162-71 [Bulgakova V. A., Poromov A. A., Grekova A. I., et al. Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups // Terapevticheskii arkhiv. 2017; 89 (1): 62-71 (in Russ.) DOI: 10.17116/terarkh201789162-71]

7. Hauge S. H., de Blasio B. F., Håberg S. E., Oakley L. Influenza hospitalizations during childhood in children born preterm // Influenza Other Respir Viruses. 2022 Mar; 16 (2): 247-254. DOI: 10.1111/irv.12908

8. Учайкин В. Ф., Шамшева О. В., Молочкова О. В., Булгакова В. А. Фармакоэпидемиологическое исследование течения гриппа и других ОРВИ в сезоне 2010/11 гг. у детей в возрасте до 18 лет // Детские инфекции. 2016; 11 (S): 9-15. [Uchaikin V. F., Shamsheva O. V., Molochkova O. V., Bulgakova V. A. Pharmacological and Epidemiological Study of the Course of Influenza and Other ARVI in the Season 2010/11 in Children under the Age of 18 // Children's infections. 2016; 11 (S): 9-15. (in Russ.)]

9. Shang M., Blanton L., Brammer L., Olsen S. J., Fry A. M. Influenza-Associated Pediatric Deaths in the United States, 2010-2016 // Pediatrics. 2018 Apr; 141 (4): e20172918. DOI: 10.1542/peds.2017-2918

10. Nair H., Widdowson M. A. Paediatric influenza vaccination: time to better protect high-risk groups? // Lancet Respir Med. 2015 Feb; 3 (2): 93-94. DOI: 10.1016/S2213-2600(14)70285-1

11. Han X., Xu P., Wang H., Mao J., Ye Q. Incident changes in the prevalence of respiratory virus among children during COVID-19 pandemic in Hangzhou, China // J Infect. 2022 Apr; 84 (4): 579-613. DOI: 10.1016/j.jinf.2022.01.007

12. https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=19389

13. Галкина С. Н., Осидак Л. В., Волощук Л. В. и др. Ранние поражения легких при гриппе // Детские инфекции. 2017; 16 (2): 13-22. [Galkina S. N., Osidak L. V., Voloshchuk L. V., еt al. Early lung lesions in influenza // Children’s infections. 2017;16 (2): 13-22 (in Russ.)]

14. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Available at: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northernhemisphere-influenza-season. Accessed 19 Sep. 2022.

15. Постановление Главного государственного санитарного врача Российской Федерации от 28.07.2022 № 20 «О мероприятиях по профилактике гриппа и острых респираторных вирусных инфекций в эпидемическом сезоне 2022-2023 годов» (Зарегистрирован 22.08.2022 № 69712)

16. Гендон Ю. З. Вакцины и химиопрепараты для профилактики гриппа // Вопросы вирусологии. 2007; 52 (1): 4-10. [Gendon Yu. Z. Vaccines and chemotherapy drugs for the prevention of influenza // Issues of Virology. 2007; 52 (1): 4-10. (in Russ.)]

17. Bulgakova V., Balabolkin I., Eliseeva T., Yusupova D. Influenza vaccination of children with atopic bronchial asthma. Allergy. 2017. 72 (S103): 361.

18. Dreskin S. C., Halsey N. A., Kelso J. M., et al. International Consensus (ICON): allergic reactions to vaccines // World Allergy Organ J. 2016 Sep 16; 9 (1): 32. DOI: 10.1186/s40413-016-0120-5

19. Echeverría-Zudaire L. A., Ortigosa-del Castillo L., Alonso-Lebrero E., et al. Consensus document on the approach to children with allergic reactions after vaccination or allergy to vaccine components. Allergol Immunopathol (Madr). 2015 May-Jun;43 (3): 304-325. DOI: 10.1016/j.aller.2015.01.004

20. Katayose M., Hosoya M., Haneda T., Yamaguchi H., Kawasaki Y., Sato M., Wright P. F. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons // Vaccine. 2011 Feb 17; 29 (9): 1844-9. DOI: 10.1016/j.vaccine.2010.12.049

21. Pepin S., Dupuy M., Borja-Tabora C. F. C., et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres // Vaccine. 2019 Mar 22; 37 (13): 1876-1884. DOI: 10.1016/j.vaccine.2018.11.074

22. Claeys C., Zaman K., Dbaibo G., et al. Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons // Lancet Child Adolesc Health. 2018 May;.2.(5):.338-349. DOI: 10.1016/S2352-4642(18)30062-2

23. Dbaibo G., Amanullah A., Claeys C., et al. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial // Pediatr Infect Dis J. 2020 Jan; 39 (1): e1-e10. DOI: 10.1097/INF.0000000000002504

24. Rolfes M. A., Goswami D., Sharmeen A. T., et al. Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh // Vaccine. 2017 Dec 15; 35 (50): 6967-6976. DOI: 10.1016/j.vaccine.2017.10.074

25. Li-Kim-Moy J. P., Yin J. K., Heron L., et al. Influenza vaccine efficacy in young children attending childcare: A randomised controlled trial // J Paediatr Child Health. 2017 Jan; 53 (1): 47-54. DOI: 10.1111/jpc.13313

26. Buchan S. A., Chung H., Campitelli M. A., et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among young children during the 2010-11 to 2013-14 influenza seasons in Ontario, Canada // PLoS One. 2017 Nov 17; 12 (11): e0187834. DOI: 10.1371/journal.pone.0187834

27. Blyth C. C., Macartney K. K., McRae J., et al. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration // Clin Infect Dis. 2019 Mar 5; 68 (6): 940-948. DOI: 10.1093/cid/ciy597

28. Blyth C. C., Jacoby P., Effler P. V., et al. Effectiveness of trivalent flu vaccine in healthy young children. Pediatrics. 2014 May;133 (5): e1218-25. DOI: 10.1542/peds.2013-3707

29. Simpson C. R., Lone N. I., Kavanagh K., et al. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study // Health Technol Assess. 2020 Dec; 24 (67): 1-66. DOI: 10.3310/hta24670

30. Jackson M. L., Chung J. R., Jackson L. A., et al. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season // N Engl J Med. 2017 Aug 10; 377 (6): 534-543. DOI: 10.1056/NEJMoa1700153

31. Pebody R. G., Whitaker H., Ellis J., et al. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19 // Vaccine. 2020 Jan 16; 38 (3): 489-497. DOI: 10.1016/j.vaccine.2019.10.071

32. Bansal A., Trieu M. C., Mohn K. G. I., Cox R. J. Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review // Front Immunol. 2021 Oct 6; 12: 744774. DOI: 10.3389/fimmu.2021.744774

33. Sugaya N., Takeuchi Y. Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan // Clin Infect Dis. 2005 Oct 1; 1 (7): 939-47. DOI: 10.1086/432938

34. Ghendon Y. Z., Kaira A. N., Elshina G. A. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly // Epidemiol Infect. 2006 Feb; 134 (1): 71-8. DOI: 10.1017/S0950268805005650

35. Yin J. K., Heywood A. E., Georgousakis M., et al. Systematic Review and Metaanalysis of Indirect Protection Afforded by Vaccinating Children Against Seasonal Influenza: Implications for Policy // Clin Infect Dis. 2017 Sep 1; 65 (5): 719-728. DOI: 10.1093/cid/cix420. PMID: 28475770

36. Shinjoh M., Furuichi M., Kobayashi H., et al. Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era // Vaccine. 2022 May 11; 40 (22): 3018-3026. DOI: 10.1016/j.vaccine.2022.04.033

37. Recommendations for Prevention and Control of Influenza in Children, 2022- 2023 // Pediatrics. 2022 Sep 6: e2022059274. DOI: 10.1542/peds.2022-059274

38. Ambrose C. S., Levin M. J. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012 Jan; 8 (1): 81-88. DOI: 10.4161/hv.8.1.17623

39. Булгакова В. А., Селимзянова Л. Р., Чемакина Д. С., Привалова Т. Е. Вакцинация против гриппа у детей – как обстоят дела в текущем сезоне // Лечащий Врач. 2020; (5): 54. https://doi.org/10.26295/OS.2020.58.32.010 [Bulgakova V. A., Selimzyanova L. R., Chemakina D. S., Privalova T. E. Vaccination against influenza in children – how it goes this season // Lechaschi Vrach. 2020; (5): 54. (in Russ.) https://doi.org/10.26295/OS.2020.58.32.010]

40. Инструкции по медицинскому применению лекарственного препарата Ультрикс® Квадри. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ba510c96-6598-4619-996a-0c3d6f4ee78d&t [Instructions for the medical use of the drug Ultrix® Quadri. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ba510c96-6598-4619-996a-0c3d6f4ee78d&t]

41. Усков А. А., Шипилов М. В., Тутельян А. В. Фармакоэкономическое обоснование использования четырехвалентной вакцины против гриппа в Российской Федерации // Инфекционные болезни. 2020; 18 (1): 96-101. DOI: 10.20953/1729-9225-2020-1-96-101 [Uskov A. A., Shipilov M. V., Tutelyan A. V. Pharmacoeconomic analysis of using a quadrivalent influenza vaccine in the Russian Federation // Infekts. bolezni (Infectious diseases). 2020; 18 (1): 96-101. (in Russ.) DOI: 10.20953/1729-9225-2020-1-96-101]

42. Esposito S., Nauta J., Lapini G., Montomoli E., van de Witte S. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study // Vaccine. 2022 Apr 20; 40 (18): 2626-2634. DOI: 10.1016/j.vaccine.2022.02.088

43. Прикладные аспекты иммунопрофилактики гриппа у детей и взрослых в период пандемии COVID-19 // Педиатрическая фармакология. 2020; 17 (6): 575-576. [Applied features of influenza immunoprophylaxis in children and adults during covid-19 pandemic // Pediatric pharmacology. 2020; 17 (6): 575-576. (In Russ.)]

44. Gagneur A., Pinquier D., Quach C. Immunization of preterm infants. Hum Vaccin Immunother 2015; 11 (11): 2556-2563. DOI: 10.1080/21645515.2015.1074358

45. Weinberger Opek M., Yeshayahu Y., Glatman-Freedman A., et al. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021 // Euro Surveill. 2021 Jul; 26(29): 2100706. DOI: 10.2807/1560-7917.ES.2021.26.29.2100706

46. Ujiie M., Tsuzuki S., Nakamoto T., Iwamoto N. Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan // Emerg Infect Dis. 2021 Nov; 27 (11): 2969-2970. DOI: 10.3201/eid2711.211565

47. Patwardhan A., Ohler A. The Flu Vaccination May Have a Protective Effect on the Course of COVID-19 in the Pediatric Population: When Does Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Meet Influenza? // Cureus. 2021 Jan 6; 13 (1): e12533. DOI: 10.7759/cureus.12533

48. Kowalska M., Niewiadomska E., Barański K., et al. Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland // Vaccines (Basel). 2021 Apr 21; 9 (5): 415. DOI: 10.3390/vaccines9050415

49. Fink G., Orlova-Fink N., Schindler T., et al. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil // BMJ Evid Based Med. 2020 Dec 11: bmjebm-2020-111549. DOI: 10.1136/bmjebm-2020-111549

50. Резолюция XX Конгресса педиатров России с международным участием «Актуальные проблемы педиатрии». Педиатрическая фармакология. 2018; 15(2): 191-192. [Resolution of the XX Congress of Russian Pediatricians with International Participation «Actual Problems of Pediatrics». Pediatric pharmacology. 2018; 15 (2): 191-192. (In Russ.)]